Neonatal Diabetes: Two Cases with Isolated Pancreas Agenesis due to Homozygous PTF1A Enhancer Mutations and One with Developmental Delay, Epilepsy, and Neonatal Diabetes Syndrome due to KCNJ11 Mutation
- PMID: 28943513
- PMCID: PMC5985387
- DOI: 10.4274/jcrpe.5162
Neonatal Diabetes: Two Cases with Isolated Pancreas Agenesis due to Homozygous PTF1A Enhancer Mutations and One with Developmental Delay, Epilepsy, and Neonatal Diabetes Syndrome due to KCNJ11 Mutation
Abstract
Neonatal diabetes mellitus is a rare form of monogenic diabetes which is diagnosed in the first six months of life. Here we report three patients with neonatal diabetes; two with isolated pancreas agenesis due to mutations in the pancreas-specific transcription factor 1A (PTF1A) enhancer and one with developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome, due to a KCNJ11 mutation. The two cases with mutations in the distal enhancer of PTF1A had a homozygous g.23508363A>G and a homozygous g.23508437A>G mutation respectively. Previous functional analyses showed that these mutations can decrease expression of PTF1A which is involved in pancreas development. Both patients were born small for gestational age to consanguineous parents. Both were treated with insulin and pancreatic enzymes. One of these patients’ fathers was also homozygous for the PTF1A mutation, whilst his partner and the parents of the other patient were heterozygous carriers. In the case with DEND sydrome, a previosly reported heterozygous KCNJ11 mutation, p.Cys166Tyr (c.497G>A), was identified. This patient was born to nonconsanguineous parents with normal birth weight. The majority of neonatal diabetes patients with KCNJ11 mutations will respond to sulphonylurea treatment. Therefore Glibenclamide, an oral antidiabetic of the sulphonylurea group, was started. This treatment regimen relatively improved blood glucose levels and neurological symptoms in the short term. Because we could not follow the patient in the long term, we are not able to draw conclusions about the efficacy of the treatment. Although neonatal diabetes mellitus can be diagnosed clinically, genetic analysis is important since it is a guide for the treatment and for prognosis.
Keywords: Neonatal diabetes; PTF1A; pancreas agenesis; KCNJ11.
Figures



Similar articles
-
Clinical Characteristics and Long-term Follow-up of Patients with Diabetes Due To PTF1A Enhancer Mutations.J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4351-9. doi: 10.1210/clinem/dgaa613. J Clin Endocrinol Metab. 2020. PMID: 32893856 Free PMC article.
-
DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea.J Korean Med Sci. 2017 Jun;32(6):1042-1045. doi: 10.3346/jkms.2017.32.6.1042. J Korean Med Sci. 2017. PMID: 28480665 Free PMC article.
-
Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan.Pediatr Diabetes. 2017 Nov;18(7):532-539. doi: 10.1111/pedi.12447. Epub 2016 Sep 29. Pediatr Diabetes. 2017. PMID: 27681997
-
Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.Diabetes Metab. 2006 Dec;32(6):569-80. doi: 10.1016/S1262-3636(07)70311-7. Diabetes Metab. 2006. PMID: 17296510 Review.
-
Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11.Rev Endocr Metab Disord. 2010 Sep;11(3):193-8. doi: 10.1007/s11154-010-9149-x. Rev Endocr Metab Disord. 2010. PMID: 20922570 Review.
Cited by
-
Multidimensional chromatin profiling of zebrafish pancreas to uncover and investigate disease-relevant enhancers.Nat Commun. 2022 Apr 11;13(1):1945. doi: 10.1038/s41467-022-29551-7. Nat Commun. 2022. PMID: 35410466 Free PMC article.
-
SOX9+/PTF1A+ Cells Define the Tip Progenitor Cells of the Human Fetal Pancreas of the Second Trimester.Stem Cells Transl Med. 2019 Dec;8(12):1249-1264. doi: 10.1002/sctm.19-0231. Epub 2019 Oct 21. Stem Cells Transl Med. 2019. PMID: 31631582 Free PMC article.
-
Clinical and molecular description of two cases of neonatal diabetes secondary to mutations in PDX1.Endocrinol Diabetes Metab Case Rep. 2023 Jul 7;2023(3):22-0383. doi: 10.1530/EDM-22-0383. Endocrinol Diabetes Metab Case Rep. 2023. PMID: 37417678 Free PMC article.
-
Pancreas agenesis mutations disrupt a lead enhancer controlling a developmental enhancer cluster.Dev Cell. 2022 Aug 22;57(16):1922-1936.e9. doi: 10.1016/j.devcel.2022.07.014. Dev Cell. 2022. PMID: 35998583 Free PMC article.
-
Single-cell RNA and transcriptome sequencing profiles identify immune-associated key genes in the development of diabetic kidney disease.Front Immunol. 2023 Mar 29;14:1030198. doi: 10.3389/fimmu.2023.1030198. eCollection 2023. Front Immunol. 2023. PMID: 37063851 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical